Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Weiss

Showing results (221-230 of 244) with videos related to

Pageof 25
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B studyD F Hayes, R Mesa-Tejada, L D Papsidero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1983
A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancerD C Tormey, V E Weinberg, J F Holland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642M E Costanza, R B Weiss, I C Henderson, et al.
Biopharmaceutics & Drug Disposition|May 1, 1997
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatinW D Figg, M C Christian, R Lush, et al.
Journal of the National Cancer Institute|December 15, 1993
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrowD P Sandler, D L Shore, J R Anderson, et al.
World Journal of Surgery|October 1, 1985
A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: a CALGB StudyW C Wood, R B Weiss, D C Tormey, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B studyR A Fleming, R L Capizzi, G L Rosner, et al.
The New England Journal of Medicine|December 3, 1987
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancerS D Williams, D M Stablein, L H Einhorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 1990
Hypersensitivity reactions from taxolR B Weiss, R C Donehower, P H Wiernik, et al.
Journal of the National Cancer Institute|August 27, 1998
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group BD R Budman, D A Berry, C T Cirrincione, et al.
Pageof 25

Showing results (221-230 of 244) with videos related to

Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B studyD F Hayes, R Mesa-Tejada, L D Papsidero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1983
A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancerD C Tormey, V E Weinberg, J F Holland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1999
Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642M E Costanza, R B Weiss, I C Henderson, et al.
Biopharmaceutics & Drug Disposition|May 1, 1997
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatinW D Figg, M C Christian, R Lush, et al.
Journal of the National Cancer Institute|December 15, 1993
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrowD P Sandler, D L Shore, J R Anderson, et al.
World Journal of Surgery|October 1, 1985
A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: a CALGB StudyW C Wood, R B Weiss, D C Tormey, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B studyR A Fleming, R L Capizzi, G L Rosner, et al.
The New England Journal of Medicine|December 3, 1987
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancerS D Williams, D M Stablein, L H Einhorn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 1990
Hypersensitivity reactions from taxolR B Weiss, R C Donehower, P H Wiernik, et al.
Journal of the National Cancer Institute|August 27, 1998
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group BD R Budman, D A Berry, C T Cirrincione, et al.
Pageof 25